Addressing overdoses from “street drugs” containing potent synthetic opioids poses a key challenge when utilizing opioid antagonists. A standard approach to known or suspected opioid overdose includes ...
Combining an opioid antagonist such as naloxone with an alpha 2-adrenergic agonist is a feasible approach for managing opioid withdrawal, results of a new Cochrane review suggest. However, it is ...
Please provide your email address to receive an email when new articles are posted on . FDA recently approved Lybalvi for the treatment of schizophrenia and for use in manic and mixed (depressive and ...
Three opioid antagonists, naloxone, naltrexone, and nalmefene, are currently approved for human use. Naloxone and nalmefene have been approved for parenteral administration and are used in the ...
FierceDrugDelivery supplied the question to Quantia MD, the provider of a physician engagement platform that counts one-third of U.S. doctors as its members. Out of 214 physicians, 66 said opioid ...
Purpose. Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP) ...
NEW YORK and BETHESDA, Md., Jan. 8, 2013 /PRNewswire/ -- TNI BioTech, Inc. (PINKSHEETS: TNIB) announced today that it has signed an agreement for the acquisition of patent rights and orphan drug ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PALM SPRINGS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results